Pacritinib + Talazoparib for Myeloproliferative Disorders
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a prospective phase I dose-escalation study, with the primary objective to access the MTD and find the RP2D of talazoparib, given in combination with standard of care dosing of pacritinib.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot be on other investigational drugs. It's best to discuss your specific medications with the trial team.
Is the combination of Pacritinib and Talazoparib safe for humans?
Talazoparib has been studied in patients with advanced breast cancer and other solid tumors, showing some side effects like fatigue, low blood cell counts, and anemia. These studies suggest that while Talazoparib can be effective, it may also cause significant side effects, especially in people with certain genetic mutations.12345
How is the drug combination of Pacritinib and Talazoparib unique for treating myeloproliferative disorders?
This drug combination is unique because it combines Pacritinib, which is a kinase inhibitor, with Talazoparib, a PARP inhibitor that helps prevent cancer cells from repairing their DNA, potentially offering a novel approach to treating myeloproliferative disorders by targeting different pathways involved in cancer cell survival.46789
What data supports the effectiveness of the drug Talazoparib?
Who Is on the Research Team?
Peter Abdelmessieh, DO, MSc
Principal Investigator
Fox Chase Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults over 18 with certain types of blood disorders like myelofibrosis or chronic leukemia, who've had symptoms measured by the MFSAF v4.0 and are considered intermediate-2/high-risk. They must have tried a JAK2 inhibitor treatment without success and have good organ function. Pregnant women, those with uncontrolled illnesses, recent other cancers, or severe unresolved treatment side effects can't join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Lead-in Phase
Pacritinib is initiated on day -7 with a standard of care dose of 200mg twice daily
Treatment
Talazoparib is administered in combination with pacritinib, with dose escalation to determine the maximum tolerated dose
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Pacritinib
- Talazoparib
Pacritinib is already approved in United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Fox Chase Cancer Center
Lead Sponsor